FindTrial
Sign In

Evaluation of the use of Ganciclovir and Letermovir in special patients and optimization of clinical dosing regimens

Evaluation of the use of Ganciclovir and Letermovir in special patients and optimization of clinical dosing regimens

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500100795
Enrollment
Unknown
Registered
2025-04-15
Start date
2023-03-31
Completion date
Unknown
Last updated
2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CMV infection

Interventions

Treatment group (Combination treatment group of Letermovir and Ganciclovir.):None

Sponsors

the First Affiliated Hospital of Xian Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1.Hematology patients undergoing allogeneic transplantation 2.Age >= 18 years 3.Development of CMV infection/viremia (CMV DNA>= 500 IU/mL) after transplantation that requires initiation of CMV treatment 4.Use of combination treatment for at least 7 days

Exclusion criteria

Exclusion criteria: 1.Use of Letermovir or Ganciclovir as monotherapy for prevention or treatment 2.Severe liver dysfunction prior to enrollment (Child-Pugh score C) 3.Survival duration of less than 1 week after medication 4.Patients taking strong inhibitors or inducers of hepatic CYP enzymes, such as Rifampicin, Phenytoin, Clarithromycin, Ritonavir, or Cobistat

Design outcomes

Primary

MeasureTime frame
Viral assessment indicators of treatment success(CMV DNA);—

Countries

China

Contacts

Public ContactYaling Dong

the First Affiliated Hospital of Xian Jiaotong University

timeflyrj@126.com+86 159 0296 2266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026